Advertisement
Singapore markets closed

  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • Dow

    37,753.31
    -45.66 (-0.12%)
     

  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     

  • Bitcoin USD

    62,690.39
    -364.41 (-0.58%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • FTSE 100

    7,861.20
    +13.21 (+0.17%)
     

  • Gold

    2,397.60
    +9.20 (+0.39%)
     

  • Crude Oil

    82.25
    -0.44 (-0.53%)
     

  • 10-Yr Bond

    4.5850
    0.0000 (0.00%)
     

  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     

  • Jakarta Composite Index

    7,166.81
    +35.97 (+0.50%)
     

  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know

Zacks Equity Research
·2-min read

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $39.45, moving -1.42% from the previous trading session. This move lagged the S&P 500's daily loss of 0.15%. At the same time, the Dow lost 0.38%, and the tech-heavy Nasdaq lost 0.05%.

Prior to today's trading, shares of the company had lost 10.07% over the past month. This has was narrower than the Medical sector's loss of 11.91% and lagged the S&P 500's loss of 7.66% in that time.

Cassava Sciences, Inc. will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.41, down 355.56% from the prior-year quarter.

Investors might also notice recent changes to analyst estimates for Cassava Sciences, Inc.Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

ADVERTISEMENT

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 72.5% lower. Cassava Sciences, Inc. currently has a Zacks Rank of #3 (Hold).

The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 104, putting it in the top 41% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cassava Sciences, Inc. (SAVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.